When sleep improves but AHI does not: comments on mepolizumab +- FESS in severe CRSwNP.

IF 5.7 2区医学 Q1 OTORHINOLARYNGOLOGY

Rhinology Pub Date : 2026-08-01 DOI:10.4193/Rhin26.159

W-Z Hong

引用次数: 0

Abstract

We read with great interest the randomized trial by Homoe et al. evaluating mepolizumab with or without functional endo-scopic sinus surgery (FESS) for severe uncontrolled CRSwNP (1), integrating patient-reported sleep outcomes (ESS, FOSQ-10, SNOT-22 sleep items) with WatchPAT-derived indices of sleep-disordered breathing (AHI/ODI). The study addresses a clinically frequent scenario in which patients report prominent fatigue and "poor sleep", while OSA may coexist and require indepen-dent management.

查看原文本刊更多论文

当睡眠改善但AHI没有改善时：mepolizumab±FESS在严重CRSwNP中的评论。

我们非常感兴趣地阅读了由homee等人进行的随机试验，该试验评估了mepolizumab联合或不联合功能性内窥镜鼻窦手术（FESS）治疗严重不受控制的CRSwNP(1)，整合了患者报告的睡眠结果（ESS, FOSQ-10， SNOT-22睡眠项目）和watchpad衍生的睡眠呼吸障碍指数（AHI/ODI）。该研究解决了临床常见的患者报告明显疲劳和“睡眠不良”的情况，而OSA可能共存，需要独立治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rhinology 医学-耳鼻喉科学

CiteScore

15.80

自引率

9.70%

发文量

135

审稿时长

6-12 weeks

期刊介绍： Rhinology serves as the official Journal of the International Rhinologic Society and is recognized as one of the journals of the European Rhinologic Society. It offers a prominent platform for disseminating rhinologic research, reviews, position papers, task force reports, and guidelines to an international scientific audience. The journal also boasts the prestigious European Position Paper in Rhinosinusitis (EPOS), a highly influential publication first released in 2005 and subsequently updated in 2007, 2012, and most recently in 2020. Employing a double-blind peer review system, Rhinology welcomes original articles, review articles, and letters to the editor.